 |
市場調査レポート
商品コード
1321973
バイオシミュレーションの世界市場 - 市場規模、シェア、成長分析：用途別（医薬品開発、創薬）、エンドユーザー別（製薬企業、バイオテクノロジー企業、学術機関、研究所） - 業界予測（2023年～2030年）Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2023-2030 |
||||||
| バイオシミュレーションの世界市場 - 市場規模、シェア、成長分析：用途別（医薬品開発、創薬）、エンドユーザー別（製薬企業、バイオテクノロジー企業、学術機関、研究所） - 業界予測（2023年～2030年） |
|
出版日: 2023年07月18日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のバイオシミュレーションの市場規模は、2021年に24億米ドル、2022年に28億1,000万米ドルとなりました。同市場は、予測期間中（2023年～2030年）に16.9%のCAGRで拡大し、2030年には97億8,000万米ドルに拡大すると予測されています。
バイオシミュレーションは、製薬・バイオテクノロジー業界で使用されている最先端技術です。生物学的プロセス、薬物相互作用、疾患メカニズムを理解するためのコンピュータモデリングとシミュレーションが含まれます。この革新的なアプローチにより、研究者は医薬品候補の結果を予測して臨床試験を最適化し、コストと製品化までの時間を削減することができます。バイオシミュレーション市場は、個別化医療に対する需要の高まりと医薬品開発の複雑化によって大きく成長しています。技術の進歩に伴い、バイオシミュレーションは創薬および薬剤開発プロセスの変革に極めて重要な役割を果たすと期待されています。
主な要因の1つはヘルスケアインフラの発展であり、高価な生物製剤に代わる費用対効果の高い代替品を提供することから、バイオシミラーの需要が増加しています。さらに、様々な疾患の有病率が上昇し、利用しやすく手頃な価格の治療に対するニーズが高まり、バイオシミラーの需要をさらに押し上げています。特許切れ医薬品の増加や進行中の臨床試験での有望な結果も、市場の拡大に寄与しています。
創薬および薬剤開発におけるバイオシミュレーション技術の利用には標準化が欠けており、生物学的事象を登録し処理するために多様なモデルや技術を採用しています。バイオシミュレーション特有の複雑さは、データやモデルの保存、操作、共有の面で研究者に課題をもたらします。標準化された手法の欠如は、効果的で信頼性の高い結果の生成を妨げ、バイオシミュレーション市場の成長を阻害しています。
当レポートは、世界のバイオシミュレーション市場について調査し、市場の概要とともに、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。
目次
エグゼクティブサマリー
親市場分析
市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 動向分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品分析
- マクロ経済指標
- トップ投資分析
- 主な成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーター分析
世界のバイオシミュレーション市場、用途別
- 市場概要
- 医薬品開発
- 創薬
- その他
世界のバイオシミュレーション市場、エンドユーザー別
- 市場概要
- 製薬会社、バイオテクノロジー企業
- 学術機関、研究所
- CRO
- その他
世界のバイオシミュレーション市場、地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- 主要企業プロファイル
- Certara
- Dassault Systemes SE
- Simulations Plus Inc.
- Schrodinger Inc.
- Physiomics Plc
- Advanced Chemistry Development Inc.
- In silico biosciences Inc.
- Genedata AG
- Evidera Inc.
- Leadscope Inc.
- Insilico Biotechnology AG
- Rhenovia Pharma SAS
- Entelos Inc.
- Biocomputing Platforms Ltd.
- Rosa & Co. LLC
- Genedata AG
- OpenEye Scientific Software Inc.
- Nexelis
- Compugen Ltd.
- Chemical Computing Group ULC
Market Insights
Bio simulation Market size was valued at USD 2.4 billion in 2021 and is poised to grow from USD 2.81 billion in 2022 to USD 9.78 billion by 2030, growing at a CAGR of 16.9% in the forecast period (2023-2030).
Biosimulation is a cutting-edge technology used in the pharmaceutical and biotechnology industries. It involves computer modeling and simulation to understand biological processes, drug interactions, and disease mechanisms. This innovative approach allows researchers to predict the outcomes of drug candidates and optimize clinical trials, reducing costs and time-to-market. The biosimulation market has witnessed substantial growth due to the increasing demand for personalized medicine and the rising complexity of drug development. As technology continues to advance, biosimulation is expected to play a pivotal role in revolutionizing drug discovery and development processes.
Top-down and bottom-up approaches were used to estimate and validate the size of bio simulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biosimulation Market Segmental Analysis
The global biosimulation market is divided into three sections: offering type, application, and end user. The market is classified into two types of offerings: software and services. The software segment is divided into the following categories: PK/PD modelling and simulation, PBPK modelling and simulation, trial simulators, molecular modelling, and others. The Biosimulation Market is classified into three applications: drug discovery, drug development, and others. End users in the Biosimulation Market include contract research organisations, pharmaceutical and biotechnology companies, research institutes, regulatory institutes, and others. By region, the Biosimulation Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver
One of the primary factors is the development of healthcare infrastructure, which has led to an increased demand for biosimilars as they offer cost-effective alternatives to expensive biologics. Additionally, the prevalence of various diseases has risen, creating a greater need for accessible and affordable treatments, further boosting the demand for biosimilars. The growing number of off-patent drugs and encouraging results from ongoing clinical trials also contribute to the market's expansion.
Restraints
The utilization of biosimulation technologies in drug discovery and development lacks standardization, employing diverse models and techniques to register and process biological events. The inherent complexity of biosimulation poses challenges for researchers in terms of data and model storage, manipulation, and sharing. The absence of standardized practices hampers the generation of effective and dependable results, impeding the growth of the biosimulation market.
Market Trends
A significant factor contributing to market expansion is the increasing occurrence of drug relapse cases attributed to drug resistance in various diseases like cancer, tuberculosis, and bacterial infections. This trend is propelling the demand for innovative solutions and technologies, including biosimulation, to address the challenges posed by drug resistance and improve treatment outcomes for patients.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Biosimulation Market by Application
- Market Overview
- drug development
- drug discovery
- and others
- Global Biosimulation Market by End user
- Market Overview
- pharmaceutical and biotechnology companies
- academic institutes and research laboratories
- contract research organisations
- and others
- Global Biosimulation Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Certara
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dassault Systemes SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Simulations Plus Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Schrodinger Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Physiomics Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Advanced Chemistry Development Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- In silico biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genedata AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Evidera Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leadscope Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Insilico Biotechnology AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rhenovia Pharma SAS
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Entelos Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocomputing Platforms Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rosa & Co. LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genedata AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OpenEye Scientific Software Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nexelis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Compugen Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chemical Computing Group ULC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
